ACOR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (12 Apr 2024 @ 04:00):

Stats
今日成交量	321 668
平均成交量	139 878
市值	821 028
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0120 (1.96%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-22	Burns Thomas M.	Buy	2 400	Non-Employee Stock Option
2023-06-22	Burns Thomas M.	Buy	0
2023-06-22	Varian John	Buy	1 200	Non-Employee Stock Option
2023-06-22	Panem Sandra Phd	Buy	1 200	Non-Employee Stock Option
2023-06-22	Kelley John P	Buy	1 200	Non-Employee Stock Option

INSIDER POWER
99.33
Last 96 transactions
Buy: 1 532 806 \| Sell: 94 790

音量相关性

長: -0.43 (neutral)

短: -0.79 (moderate negative)

Signal:(18.947) Neutral

Acorda Therapeutics Inc 相关性

10 最正相关
HCTI	0.95
TVTX	0.945
ALBO	0.939
MNST	0.934
CMPI	0.93
GNLN	0.929
APLT	0.929
MORF	0.924
SBET	0.922
UFO	0.922

10 最负相关
NTGR	-0.928
PI	-0.928
ATRS	-0.919
PPBT	-0.916
HONE	-0.912
CPSI	-0.912
BRAC	-0.908
KDNY	-0.907
MSAC	-0.903
LGTO	-0.901

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Acorda Therapeutics Inc 相关性 - 货币/商品

0.10
( neutral )

0.12
( neutral )

0.41
( neutral )

0.52
( weak )

0.31
( neutral )

Acorda Therapeutics Inc 财务报表

Annual	2023
营收:	$117.63M
毛利润:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2023
营收:	$117.63M
毛利润:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2022
营收:	$118.57M
毛利润:	$88.23M (74.42 %)
EPS:	$-66.90

FY	2021
营收:	$129.07M
毛利润:	$88.28M (68.40 %)
EPS:	$-12.86

Financial Reports:

No articles found.

Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

实时更新： Acorda Therapeutics Inc [ACOR]

Upcoming Earnings Alert